Abstract |
In the last few years, the treatment of castration-resistant prostate carcinoma (CRPC) has changed completely. The approval of docetaxel and subsequent investigation in this field have led to development of new agents that have demonstrated an improvement in overall survival in the post- docetaxel setting, such as cabazitaxel and abiraterone. Radium-223 chloride is a radioisotope that has recently shown efficacy after docetaxel and in patients unfit for docetaxel, with improvements in overall survival and the time to the first skeletal-related event, compared with placebo, without increasing toxicity. These findings have made this agent a new option for treatment of these patients in the near future.
|
Authors | Alvaro Pinto, Patricia Cruz |
Journal | Drugs in R&D
(Drugs R D)
Vol. 12
Issue 4
Pg. 227-33
(Dec 01 2012)
ISSN: 1179-6901 [Electronic] New Zealand |
PMID | 23190319
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antineoplastic Agents
- Radioisotopes
- radium Ra 223 dichloride
- Radium
|
Topics |
- Antineoplastic Agents
(therapeutic use)
- Carcinoma
(drug therapy, surgery)
- Humans
- Male
- Orchiectomy
- Prostatic Neoplasms
(drug therapy, radiotherapy, surgery)
- Radioisotopes
(therapeutic use)
- Radium
(therapeutic use)
|